AMNEAL PHARMACEUTICALS, INC. Most Important Performance Measures
The measures each proxy statement lists as most important for linking pay to performance (Item 402(v) tabular list), as tagged, newest proxy first.
- 2023-03-24: Measure Adjusted EBITDA.
- 2023-03-24: Measure Stock Price.
- 2024-03-22: Measure Adjusted EBITDA.
- 2024-03-22: Measure Stock Price.
| Proxy filed | Measure |
|---|---|
| 2023-03-24 | Adjusted EBITDA |
| 2023-03-24 | Stock Price |
| 2024-03-22 | Adjusted EBITDA |
| 2024-03-22 | Stock Price |
| 2025-03-25 | Adjusted EBITDA |
| 2025-03-25 | Stock Price |
| 2026-03-25 | Adjusted EBITDA |
| 2026-03-25 | Stock Price |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |